Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2006 August;141(4) > Giornale Italiano di Dermatologia e Venereologia 2006 August;141(4):415-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

THERAPEUTICAL NOTES  


Giornale Italiano di Dermatologia e Venereologia 2006 August;141(4):415-9

language: English

The use of pimecrolimus cream 1% in the treatment of facial psoriasis

Frigerio E., Taglioni M., Franchi C., Garutti C., Spadino S., Altomare A., Altomare G. F.

Department of Dermatology, IRCCS Galeazzi Hospital University of Milan, Milan, Italy


PDF  


Aim. To evaluate the efficacy of pimecrolimus cream 1% in patients with facial psoriasis.
Methods. In this open study, 40 patients of both sexes (27 males and 13 females) aged between 18 and 75 years (mean age: 48.3 years) with psoriasis vulgaris affecting also the face (PASI ≤12) have been treated with pimecrolimus cream 1%. The drug has been applied to the facial lesions twice daily for 2 months.
Results. Upon completion of treatment, the complete resolution of the lesions has been documented in 42.5% of cases (17 patients), and an improvement in all symptoms of erythema, desquamation and infiltration in 52.5% of cases (21 patients). Only 1 patient interrupted the treatment due to intolerance to the drug.
Conclusions. In our study pimecrolimus cream 1% has shown a high level of efficacy and good tolerability in the majority of cases treated, revealing itself to be a valid therapeutic option in the treatment of facial psoriasis.

top of page

Publication History

Cite this article as

Corresponding author e-mail